SiteOne Therapeutics is focused on developing innovative therapeutics aimed at addressing disorders related to the peripheral nervous system (PNS). The company recognizes that pathological changes in the PNS can lead to sensory hyperexcitability, which is a common feature in various disease states. To combat these issues, SiteOne is advancing a pipeline of clinical-stage therapeutics that includes selective inhibitors of sodium channels, as well as other targets that have been validated both genetically and clinically. This approach aims to provide effective pain relief and manage sensory disorders while potentially mitigating the addiction risks associated with traditional pain management therapies.

The therapeutic strategies employed by SiteOne Therapeutics are designed to specifically target the underlying mechanisms of pain and sensory hyperexcitability. By focusing on the PNS, the company seeks to develop treatments that are not only effective but also safer alternatives to existing options. Their commitment to addressing these complex conditions reflects a broader understanding of the PNS's role in overall health and disease, positioning SiteOne as a key player in the development of next-generation pain management solutions.

United States

SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as pain, itch, and cough. The company is advancing a novel class of highly selective small molecule inhibitors to target Nav1.7, Nav1.8, and Nav1.9 sodium ion channels. SiteOne Therapeutics is dedicated to the development of novel therapeutics to safely and effectively treat pain and other hypersensitivity disorders.

SiteOne Therapeutics

Company Details